Raras
Buscar doenças, sintomas, genes...
Degenerescência cerebelar paraneoplásica
ORPHA:623626CID-10 · G31.8CID-11 · 8E4A.0DOENÇA RARA

[THOUGHT] The user wants a translation of a medical description into accessible Brazilian Portuguese. I need to maintain accuracy but use simple terms. I must return ONLY the translated text, no prefácio. Original text: "A rare, immune-mediated disorder characterized by cerebellar degeneration due to the presence of an often undetected malignancy (usually carcinoma or lymphoma) in an anatomic site other than the cerebellum. Signs and symptoms include progressive ataxia, dysarthria, and nystagmus." Let's break it down and simplify each part: 1. **"A rare, immune-mediated disorder"**: * "rare": raro * "immune-mediated disorder": uma doença causada pelo sistema de defesa do corpo (sistema imunológico) agindo de forma errada contra ele mesmo. "Doença autoimune" é uma boa simplificação, mas "mediado por autoimunidade" é mais literal. Let's try "uma doença rara em que o próprio sistema de defesa do corpo ataca o organismo". Or "uma doença rara causada por uma resposta errada do sistema imunológico". "Doença autoimune" might be too strong if it's "immune-mediated" and not strictly "autoimmune". Let's go with "uma doença rara em que o próprio sistema de defesa do corpo (o sistema imunológico) ataca as células". Or more simply "uma doença rara causada por uma ação errada do sistema imunológico (o sistema de defesa do corpo)". Let's try "uma doença rara em que o próprio sistema de defesa do corpo (o sistema imunológico) reage de forma errada". 2. **"characterized by cerebellar degeneration"**: * "characterized by": caracterizada por * "cerebellar degeneration": degeneração do cerebelo. Cerebelo é uma parte do cérebro. Degeneração significa que ele está estragando ou perdendo função. So, "caracterizada pela degeneração (ou seja, o estrago) do cerebelo, que é uma parte do cérebro". Or simpler: "que causa um estrago no cerebelo (uma parte do cérebro)". 3. **"due to the presence of an often undetected malignancy (usually carcinoma or lymphoma) in an anatomic site other than the cerebellum."**: * "due to the presence of": por causa da presença de * "an often undetected malignancy": um câncer (tumor maligno) que muitas vezes não é descoberto. "Malignancy" is "tumor maligno" or "câncer". "Often undetected" means "muitas vezes não detectado" or "que frequentemente passa despercebido". * "(usually carcinoma or lymphoma)": (geralmente um tipo de câncer chamado carcinoma ou linfoma). * "in an anatomic site other than the cerebellum": em outro lugar do corpo que não seja o cerebelo. "Anatomic site" -> "local do corpo". "Other than the cerebellum" -> "que não seja o cerebelo". * Combining this: "causado pela presença de um câncer (tumor maligno), muitas vezes não detectado, em outra parte do corpo que não o cerebelo (geralmente um tipo de câncer chamado carcinoma ou linfoma)". * Let's refine: "Essa degeneração acontece por causa de um câncer (tumor maligno) que costuma ser difícil de encontrar e está localizado em alguma outra parte do corpo, não no cerebelo (geralmente é um tipo de câncer como carcinoma ou linfoma)." 4. **"Signs and symptoms include progressive ataxia, dysarthria, and nystagmus."**: * "Signs and symptoms": Os sinais e sintomas. Or "Os sinais da doença incluem". * "progressive ataxia": ataxia progressiva. Ataxia é falta de coordenação. Progressiva significa que piora com o tempo. "dificuldade progressiva de coordenação dos movimentos". * "dysarthria": disartria. Disartria é dificuldade para articular as palavras. "dificuldade para falar, como se as palavras saíssem arrastadas". * "nystagmus": nistagmo. Nistagmo é movimento involuntário dos olhos. "movimentos involuntários dos olhos". * Combining this: "Os sinais e sintomas incluem dificuldade progressiva de coordenação dos movimentos (ataxia), dificuldade para falar (disartria) e movimentos involuntários dos olhos (nistagmo)." Let's try to put it all together: "É uma doença rara em que o próprio sistema de defesa do corpo (o sistema imunológico) reage de forma errada. Ela é caracterizada pelo estrago do cerebelo (uma parte do cérebro). Esse estrago acontece por causa da presença de um câncer (tumor maligno) que muitas vezes não é detectado e está localizado em outra parte do corpo que não o cerebelo (geralmente é um tipo de câncer como carcinoma ou linfoma). Os sinais e sintomas incluem dificuldade progressiva de coordenação dos movimentos (ataxia), dificuldade para falar (disartria) e movimentos involuntários dos olhos (nistagmo)." This sounds quite good and accessible. Let's review for precision and simplicity. "A rare, immune-mediated disorder" -> "É uma doença rara em que o próprio sistema de defesa do corpo (o sistema imunológico) reage de forma errada." - Good. "Ataca a si mesmo" might be even simpler than "reage de forma errada". "Doença autoimune" is the simplest and most common term for "immune-mediated" disorders where the immune system attacks the body's own tissues. I think it's acceptable here for accessibility. Let's try "É uma doença rara, considerada autoimune". "characterized by cerebellar degeneration" -> "caracterizada pelo estrago do cerebelo (uma parte do cérebro)." - "Estrago" is simple. "Degeneração" can be kept if explained or "deterioração". Let's stick with "estrago" for simplicity. "due to the presence of an often undetected malignancy (usually carcinoma or lymphoma) in an anatomic site other than the cerebellum." -> "que acontece devido à presença de um câncer (tumor maligno) que muitas vezes não é encontrado. Esse câncer está localizado em outra parte do corpo que não o cerebelo (geralmente é um tipo de câncer como carcinoma ou linfoma)." - This is good. "Costuma passar despercebido" instead of "muitas vezes não é encontrado" is also good. "Signs and symptoms include progressive ataxia, dysarthria, and nystagmus." -> "Os sinais e sintomas incluem dificuldade progressiva de coordenação dos movimentos (ataxia), dificuldade para falar (disartria) e movimentos involuntários dos olhos (nistagmo)." - Excellent. Let's try again with the "autoimune" simplification: "É uma doença rara, considerada autoimune, que causa um estrago no cerebelo (uma parte do cérebro). Esse problema ocorre por causa de um câncer (tumor maligno) que muitas vezes passa despercebido e está localizado em outra parte do corpo, não no cerebelo (geralmente é um tipo de câncer como carcinoma ou linfoma). Os sinais e sintomas incluem dificuldade progressiva de coordenação dos movimentos (chamada ataxia), dificuldade para falar (disartria) e movimentos involuntários dos olhos (nistagmo)." This version is even more concise and direct. "Considerada autoimune" handles "immune-mediated" well for an accessible context. "causa um estrago no cerebelo" is very simple and clear for "cerebellar degeneration". "Esse problema ocorre por causa de um câncer (tumor maligno) que muitas vezes passa despercebido" is excellent for "due to the presence of an often undetected malignancy". "está localizado em outra parte do corpo, não no cerebelo" is clear for "in an anatomic site other than the cerebellum". The explanation for symptoms is good. Final check on "immune-mediated": while "autoimune" implies the immune system *directly* attacks healthy tissues, "immune-mediated" can be broader (e.g., inflammation *triggered* by immune responses, but not necessarily a direct attack on self). However, in the context of paraneoplastic syndromes (which this description sounds like), the immune response *is* directed against healthy tissues due to molecular mimicry with the tumor. So, "autoimune" or "com mecanismo autoimune" is generally accepted as an accessible explanation. "Considerada autoimune" makes it safe. Let's consider "carcinoma or lymphoma". Maybe just "tipos de câncer como carcinoma ou linfoma" is enough. One more pass: "É uma doença rara, de origem autoimune, que se caracteriza pela deterioração do cerebelo (uma parte do cérebro). Isso acontece por causa da presença de um câncer (tumor maligno) que, frequentemente, não é detectado e está localizado em alguma outra parte do corpo que não o cerebelo (geralmente é um tipo de câncer como carcinoma ou linfoma). Os sinais e sintomas incluem dificuldade progressiva de coordenação dos movimentos (ataxia), dificuldade para falar (disartria) e movimentos involuntários dos olhos (nistagmo)." "Deterioração" is a bit more formal than "estrago" but still accessible. "De origem autoimune" is good. "frequentemente, não é detectado" is good. I think this version maintains precision while being simple. Let's stick to the last one. "Deterioração" is better than "estrago" for medical context, still simple enough. "De origem autoimune" is good. "frequentemente, não é detectado" is concise. The rest is clear.É uma doença rara, de origem autoimune, que se caracteriza pela deterioração do cerebelo (uma parte do cérebro). Isso acontece por causa da presença de um câncer (tumor maligno) que, frequentemente, não é detectado e está localizado em alguma outra parte do corpo que não o cerebelo (geralmente é um tipo de câncer como carcinoma ou linfoma). Os sinais e sintomas incluem dificuldade progressiva de coordenação dos movimentos (ataxia), dificuldade para falar (disartria) e movimentos involuntários dos olhos (nistagmo).

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

[THOUGHT] The user wants a translation of a medical description into accessible Brazilian Portuguese. I need to maintain accuracy but use simple terms. I must return ONLY the translated text, no prefácio. Original text: "A rare, immune-mediated disorder characterized by cerebellar degeneration due to the presence of an often undetected malignancy (usually carcinoma or lymphoma) in an anatomic site other than the cerebellum. Signs and symptoms include progressive ataxia, dysarthria, and nystagmus." Let's break it down and simplify each part: 1. **"A rare, immune-mediated disorder"**: * "rare": raro * "immune-mediated disorder": uma doença causada pelo sistema de defesa do corpo (sistema imunológico) agindo de forma errada contra ele mesmo. "Doença autoimune" é uma boa simplificação, mas "mediado por autoimunidade" é mais literal. Let's try "uma doença rara em que o próprio sistema de defesa do corpo ataca o organismo". Or "uma doença rara causada por uma resposta errada do sistema imunológico". "Doença autoimune" might be too strong if it's "immune-mediated" and not strictly "autoimmune". Let's go with "uma doença rara em que o próprio sistema de defesa do corpo (o sistema imunológico) ataca as células". Or more simply "uma doença rara causada por uma ação errada do sistema imunológico (o sistema de defesa do corpo)". Let's try "uma doença rara em que o próprio sistema de defesa do corpo (o sistema imunológico) reage de forma errada". 2. **"characterized by cerebellar degeneration"**: * "characterized by": caracterizada por * "cerebellar degeneration": degeneração do cerebelo. Cerebelo é uma parte do cérebro. Degeneração significa que ele está estragando ou perdendo função. So, "caracterizada pela degeneração (ou seja, o estrago) do cerebelo, que é uma parte do cérebro". Or simpler: "que causa um estrago no cerebelo (uma parte do cérebro)". 3. **"due to the presence of an often undetected malignancy (usually carcinoma or lymphoma) in an anatomic site other than the cerebellum."**: * "due to the presence of": por causa da presença de * "an often undetected malignancy": um câncer (tumor maligno) que muitas vezes não é descoberto. "Malignancy" is "tumor maligno" or "câncer". "Often undetected" means "muitas vezes não detectado" or "que frequentemente passa despercebido". * "(usually carcinoma or lymphoma)": (geralmente um tipo de câncer chamado carcinoma ou linfoma). * "in an anatomic site other than the cerebellum": em outro lugar do corpo que não seja o cerebelo. "Anatomic site" -> "local do corpo". "Other than the cerebellum" -> "que não seja o cerebelo". * Combining this: "causado pela presença de um câncer (tumor maligno), muitas vezes não detectado, em outra parte do corpo que não o cerebelo (geralmente um tipo de câncer chamado carcinoma ou linfoma)". * Let's refine: "Essa degeneração acontece por causa de um câncer (tumor maligno) que costuma ser difícil de encontrar e está localizado em alguma outra parte do corpo, não no cerebelo (geralmente é um tipo de câncer como carcinoma ou linfoma)." 4. **"Signs and symptoms include progressive ataxia, dysarthria, and nystagmus."**: * "Signs and symptoms": Os sinais e sintomas. Or "Os sinais da doença incluem". * "progressive ataxia": ataxia progressiva. Ataxia é falta de coordenação. Progressiva significa que piora com o tempo. "dificuldade progressiva de coordenação dos movimentos". * "dysarthria": disartria. Disartria é dificuldade para articular as palavras. "dificuldade para falar, como se as palavras saíssem arrastadas". * "nystagmus": nistagmo. Nistagmo é movimento involuntário dos olhos. "movimentos involuntários dos olhos". * Combining this: "Os sinais e sintomas incluem dificuldade progressiva de coordenação dos movimentos (ataxia), dificuldade para falar (disartria) e movimentos involuntários dos olhos (nistagmo)." Let's try to put it all together: "É uma doença rara em que o próprio sistema de defesa do corpo (o sistema imunológico) reage de forma errada. Ela é caracterizada pelo estrago do cerebelo (uma parte do cérebro). Esse estrago acontece por causa da presença de um câncer (tumor maligno) que muitas vezes não é detectado e está localizado em outra parte do corpo que não o cerebelo (geralmente é um tipo de câncer como carcinoma ou linfoma). Os sinais e sintomas incluem dificuldade progressiva de coordenação dos movimentos (ataxia), dificuldade para falar (disartria) e movimentos involuntários dos olhos (nistagmo)." This sounds quite good and accessible. Let's review for precision and simplicity. "A rare, immune-mediated disorder" -> "É uma doença rara em que o próprio sistema de defesa do corpo (o sistema imunológico) reage de forma errada." - Good. "Ataca a si mesmo" might be even simpler than "reage de forma errada". "Doença autoimune" is the simplest and most common term for "immune-mediated" disorders where the immune system attacks the body's own tissues. I think it's acceptable here for accessibility. Let's try "É uma doença rara, considerada autoimune". "characterized by cerebellar degeneration" -> "caracterizada pelo estrago do cerebelo (uma parte do cérebro)." - "Estrago" is simple. "Degeneração" can be kept if explained or "deterioração". Let's stick with "estrago" for simplicity. "due to the presence of an often undetected malignancy (usually carcinoma or lymphoma) in an anatomic site other than the cerebellum." -> "que acontece devido à presença de um câncer (tumor maligno) que muitas vezes não é encontrado. Esse câncer está localizado em outra parte do corpo que não o cerebelo (geralmente é um tipo de câncer como carcinoma ou linfoma)." - This is good. "Costuma passar despercebido" instead of "muitas vezes não é encontrado" is also good. "Signs and symptoms include progressive ataxia, dysarthria, and nystagmus." -> "Os sinais e sintomas incluem dificuldade progressiva de coordenação dos movimentos (ataxia), dificuldade para falar (disartria) e movimentos involuntários dos olhos (nistagmo)." - Excellent. Let's try again with the "autoimune" simplification: "É uma doença rara, considerada autoimune, que causa um estrago no cerebelo (uma parte do cérebro). Esse problema ocorre por causa de um câncer (tumor maligno) que muitas vezes passa despercebido e está localizado em outra parte do corpo, não no cerebelo (geralmente é um tipo de câncer como carcinoma ou linfoma). Os sinais e sintomas incluem dificuldade progressiva de coordenação dos movimentos (chamada ataxia), dificuldade para falar (disartria) e movimentos involuntários dos olhos (nistagmo)." This version is even more concise and direct. "Considerada autoimune" handles "immune-mediated" well for an accessible context. "causa um estrago no cerebelo" is very simple and clear for "cerebellar degeneration". "Esse problema ocorre por causa de um câncer (tumor maligno) que muitas vezes passa despercebido" is excellent for "due to the presence of an often undetected malignancy". "está localizado em outra parte do corpo, não no cerebelo" is clear for "in an anatomic site other than the cerebellum". The explanation for symptoms is good. Final check on "immune-mediated": while "autoimune" implies the immune system *directly* attacks healthy tissues, "immune-mediated" can be broader (e.g., inflammation *triggered* by immune responses, but not necessarily a direct attack on self). However, in the context of paraneoplastic syndromes (which this description sounds like), the immune response *is* directed against healthy tissues due to molecular mimicry with the tumor. So, "autoimune" or "com mecanismo autoimune" is generally accepted as an accessible explanation. "Considerada autoimune" makes it safe. Let's consider "carcinoma or lymphoma". Maybe just "tipos de câncer como carcinoma ou linfoma" is enough. One more pass: "É uma doença rara, de origem autoimune, que se caracteriza pela deterioração do cerebelo (uma parte do cérebro). Isso acontece por causa da presença de um câncer (tumor maligno) que, frequentemente, não é detectado e está localizado em alguma outra parte do corpo que não o cerebelo (geralmente é um tipo de câncer como carcinoma ou linfoma). Os sinais e sintomas incluem dificuldade progressiva de coordenação dos movimentos (ataxia), dificuldade para falar (disartria) e movimentos involuntários dos olhos (nistagmo)." "Deterioração" is a bit more formal than "estrago" but still accessible. "De origem autoimune" is good. "frequentemente, não é detectado" is good. I think this version maintains precision while being simple. Let's stick to the last one. "Deterioração" is better than "estrago" for medical context, still simple enough. "De origem autoimune" is good. "frequentemente, não é detectado" is concise. The rest is clear.É uma doença rara, de origem autoimune, que se caracteriza pela deterioração do cerebelo (uma parte do cérebro). Isso acontece por causa da presença de um câncer (tumor maligno) que, frequentemente, não é detectado e está localizado em alguma outra parte do corpo que não o cerebelo (geralmente é um tipo de câncer como carcinoma ou linfoma). Os sinais e sintomas incluem dificuldade progressiva de coordenação dos movimentos (ataxia), dificuldade para falar (disartria) e movimentos involuntários dos olhos (nistagmo).

Publicações científicas
672 artigos
Último publicado: 2026 Mar

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
1-9 / 1 000 000
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
0.9553
Europe
Início
All ages
🏥
SUS: Cobertura mínimaScore: 15%
CID-10: G31.8
🇧🇷Dados SUS / DATASUS
PROCEDIMENTOS SIGTAP (2)
0202010694
Sequenciamento completo do exoma (WES)genetic_test
0301070040
Atendimento em reabilitação — doenças rarasrehabilitation
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🧠
Neurológico
4 sintomas
🫃
Digestivo
2 sintomas
👁️
Olhos
1 sintomas
🩸
Sangue
1 sintomas
🛡️
Imunológico
1 sintomas

+ 15 sintomas em outras categorias

Características mais comuns

55%prev.
Aumento da concentração de proteína no LCR
Frequente (79-30%)
55%prev.
Pleocitose do LCR
Frequente (79-30%)
55%prev.
Ataxia
Frequente (79-30%)
55%prev.
Bandas oligoclonais de imunoglobulina G no LCR
Frequente (79-30%)
17%prev.
Náusea e vômito
Ocasional (29-5%)
17%prev.
Anticorpo anti-Ri
Ocasional (29-5%)
24sintomas
Frequente (4)
Ocasional (20)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 24 características clínicas mais associadas, ordenadas por frequência.

Aumento da concentração de proteína no LCRIncreased CSF protein concentration
Frequente (79-30%)55%
Pleocitose do LCRCSF pleocytosis
Frequente (79-30%)55%
Ataxia
Frequente (79-30%)55%
Bandas oligoclonais de imunoglobulina G no LCRCSF oligoclonal immunoglobulin G bands
Frequente (79-30%)55%
Náusea e vômitoNausea and vomiting
Ocasional (29-5%)17%

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico672PubMed
Últimos 10 anos200publicações
Pico202440 papers
Linha do tempo
2026Hoje · 2026🧪 2008Primeiro ensaio clínico📈 2024Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

🧬

Nenhum gene associado encontrado

Os dados genéticos desta condição ainda estão sendo catalogados.

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Degenerescência cerebelar paraneoplásica

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

Pesquisa e ensaios clínicos

Nenhum ensaio clínico registrado para esta condição.

🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
275 papers (10 anos)
#1

Prolonged Anti-Zic4 Antibody-Positive Cerebellar Degeneration Following COVID-19 Infection.

Neuropsychopharmacology reports2026 Mar

Although anti-Zic4 antibodies are associated with paraneoplastic cerebellar degeneration, predominantly in small-cell lung carcinoma, their role in postinfectious autoimmunity remains poorly understood. Here, we report a 53-year-old woman who developed progressive cerebellar degeneration following coronavirus disease 2019 (COVID-19), characterized by isolated anti-Zic4 antibody positivity in the absence of malignancy. Two months after developing mild respiratory symptoms, she developed dysarthria, imbalance, and gait ataxia. Neurological examination revealed gaze-evoked nystagmus, broad-based ataxia, and cerebellar dysmetria. Brain MRI demonstrated marked cerebellar atrophy, while cerebrospinal fluid analysis showed elevated protein, increased IgG index, and the presence of oligoclonal bands. Serological testing confirmed strong anti-Zic4 antibody positivity. Initial treatment with intravenous immunoglobulin and plasmapheresis achieved transient improvement and decreased antibody titers. However, 1 year later, recurrence of antibodies coincided with further cerebellar atrophy and posterior hypoperfusion on MRI and SPECT, despite maintenance immunotherapy with low-dose corticosteroids and periodic IVIG. Cognitive function was well preserved, highlighting the selective vulnerability of cerebellar circuits. This case illustrates an unusual phenotype of prolonged, isolated anti-Zic4 antibody-associated cerebellar degeneration triggered by SARS-CoV-2 infection, thus expanding the recognized clinical spectrum of Zic4-related disorders beyond paraneoplastic contexts. The underlying immunopathological mechanisms have yet to be elucidated. Notably, radiological progression was disproportionate to clinical stabilization, underscoring the necessity of long-term clinical/imaging surveillance. This case highlights the need for further studies to clarify pathophysiological links between COVID-19 and persistent autoimmune cerebellar degeneration.

#2

Paraneoplastic cerebellar degeneration from an isolated nodal clear cell carcinoma of suspected gynecologic origin: case report and literature review.

Journal of cancer research and clinical oncology2026 Jan 27

Paraneoplastic cerebellar degeneration (PCD) is a rare neurologic syndrome that often presents before an underlying malignancy is diagnosed. Patients typically develop subacute cerebellar symptoms—such as vertigo, dysmetria, disconjugate gaze, and dysarthria—before any tumor is detected. Establishing the diagnosis involves ruling out metastatic disease, treatment toxicity, infection, and metabolic disturbances, and often hinges on finding antineuronal antibodies (most commonly anti-Yo, also called type-1 anti-Purkinje cell antibody or PCA-1) in blood or cerebrospinal fluid (CSF). Anti-Yo positivity is classically linked to breast or gynecologic cancers and carries a poor prognosis. We describe a 56-year-old woman with a remote history of parotid basal cell adenocarcinoma who developed gradually worsening cerebellar dysfunction over several months, despite negative initial imaging and routine laboratory tests. When more extensive antibody testing revealed high-titer anti-Yo antibodies in serum and CSF, our suspicion for a paraneoplastic process increased. Subsequent FDG-PET/CT identified FDG-avid pelvic lymph nodes, and surgical pathology confirmed metastatic clear cell carcinoma in two iliac nodes, although the uterus, ovaries, and fallopian tubes were entirely benign. The patient received plasma exchange, intravenous immunoglobulin (IVIG), high-dose steroids, and adjuvant carboplatin/paclitaxel. Although she experienced some improvement in speech and upper-limb coordination, she remains non-ambulatory with persistent cerebellar deficits, three years after initial presentation. This case illustrates how anti-Yo PCD can foreshadow an occult nodal gynecologic malignancy without an identifiable primary tumor, highlighting the need for an extensive workup—including advanced metabolic imaging and, sometimes, empiric surgical exploration—when initial evaluations are unrevealing. Early tumor localization and treatment of both the malignancy and autoimmune response remain crucial to optimizing neurologic outcomes.

#3

Paraneoplastic Neuro-Ophthalmologic Symptoms as Initial Manifestation of Hodgkin Lymphoma.

Hematology reports2026 Jan 05

Background and Clinical Significance: Patients with Hodgkin lymphoma (HL) often present with lymphadenopathy, biochemical inflammation, and constitutional symptoms, but may experience symptoms from extra-nodal organs. Symptoms are caused by either lymphoma or a paraneoplastic phenomenon but overt central nervous system (CNS) involvement in HL is very uncommon. However, in rare cases, paraneoplastic neuro-ophthalmologic manifestations occur. Case Presentation: This case report describes a young female diagnosed with HL initially presenting with visual loss, reduced visual field, impaired balance, and sensory disturbances but no evidence of CNS-lymphoma. After treatment with bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisolone (escalated BEACOPP), she experienced full recovery of all neurological and ophthalmological symptoms. She experienced complete remission without any signs of relapse at follow-up after 2.5 years. Paraneoplastic cerebellar degeneration (PCD) related to HL have been described as a rare neurological syndrome, with varying neurological symptoms preceding the diagnosis of HL. PCD is typically associated with anti-Tr antibodies. Despite being negative for anti-Tr antibodies in both serum and cerebrospinal fluid (CSF), the neuro-ophthalmologic symptoms were interpreted as a paraneoplastic phenomenon in HL resembling PCD. The exact pathophysiology in this case is unknown but might be associated with undetected antigens and T-cell-mediated autoimmunity because of the presence of non-malignant T-cells in the CSF. Conclusions: This manuscript describes a case of an atypical presentation of HL with neuro-ophthalmologic symptoms which fully recovered upon anti-lymphoma treatment. Because of the good prognosis, we aim to emphasize the awareness of rare cases of HL initially presenting such manifestations to avoid diagnostic delays.

#4

Autologous Hematopoietic Stem Cell Transplantation for Paraneoplastic Cerebellar Degeneration.

Neurology(R) neuroimmunology &amp; neuroinflammation2025 Sep

The aim of this study was to describe 2 patients with paraneoplastic cerebellar degeneration (PCD) treated with autologous hematopoietic stem cell transplantation (AHSCT). Off-label AHSCT was performed at Hospital Clinic Barcelona, including stem cell mobilization (cyclophosphamide, filgrastim), plasma exchange, and a nonmyeloablative regimen (cyclophosphamide, antithymocyte globulin, rituximab [RTX]). A 38-year-old woman developed anti-Yo-associated PCD 17 months after treatment of a gynecologic cancer (without evidence of tumor recurrence). Despite treatment with steroids and RTX, she became unable to walk. AHSCT resulted in progressive improvement, no longer needing assistance to walk 9 months after AHSCT. Tumor recurrence, without neurologic worsening, was identified 16 months after AHSCT, and chemotherapy was restarted. At the last follow-up (46 months), she continues on chemotherapy without neurologic deterioration. A 48-year-old man developed PCD associated with Tr/delta/notch-like epidermal growth factor-related receptor antibodies. Axillary lymph node biopsy demonstrated Hodgkin lymphoma. Chemoradiation resulted in complete tumor response, but cerebellar ataxia worsened despite treatment with steroids and IV immunoglobulins. Ten months after cerebellar symptom onset, he underwent AHSCT resulting in neurologic improvement. At the last follow-up, 39 months after AHSCT, he remains independent in activities of daily living. In our experience, AHSCT is worth to be considered in patients with progressive PCD refractory to conventional oncological and immunotherapy treatments. This is a single observational study without controls and provides Class IV evidence.

#5

CDR2 is a dynein adaptor recruited by kinectin to regulate ER sheet organization.

The Journal of cell biology2025 Sep 01

The ER relies on the microtubule cytoskeleton for the organization of its extended membrane network, but how microtubule-based motors contribute remains unclear. Using biochemical and cell-based assays, we identify cerebellar degeneration-related protein 2 (CDR2) and its paralog CDR2-like (CDR2L), onconeural antigens with poorly understood functions, as ER adaptors for cytoplasmic dynein-1 (dynein). We demonstrate in human cancer cells that CDR2 is recruited by the integral ER membrane protein kinectin (KTN1) and that double knockout of CDR2 and CDR2L enhances KTN1-dependent ER sheet stacking, reversal of which by exogenous CDR2 requires its dynein-binding CC1 box motif. Exogenous CDR2 expression additionally promotes CC1 box-dependent clustering of ER sheets near centrosomes. CDR2 competes with the eEF1Bβ subunit of translation elongation factor 1 for binding to KTN1, and eEF1Bβ knockdown increases endogenous CDR2 levels on ER sheets, inducing their centrosome-proximal clustering. Our study describes a novel molecular pathway that implicates dynein in ER sheet organization and may be involved in the pathogenesis of paraneoplastic cerebellar degeneration.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC433 artigos no totalmostrando 194

2026

Prolonged Anti-Zic4 Antibody-Positive Cerebellar Degeneration Following COVID-19 Infection.

Neuropsychopharmacology reports
2025

Late-onset anti-Yo antibody-positive paraneoplastic cerebellar degeneration: a case report.

Frontiers in surgery
2026

Paraneoplastic cerebellar degeneration from an isolated nodal clear cell carcinoma of suspected gynecologic origin: case report and literature review.

Journal of cancer research and clinical oncology
2026

Paraneoplastic Neuro-Ophthalmologic Symptoms as Initial Manifestation of Hodgkin Lymphoma.

Hematology reports
2025

Paraneoplastic Cerebellar Syndrome Revealing Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer: A Case Report.

Cureus
2025

Paraneoplastic Cerebellar Degeneration from Subclinical Breast Cancer on Mammography.

JMA journal
2025

A Rare Presentation of Dizziness: Vestibular Testing in Paraneoplastic Cerebellar Degeneration.

Journal of the American Academy of Audiology
2025

A case of Anti-Hu and Anti-Zic4 paraneoplastic cerebellar degeneration in a patient with stage IV adenocarcinoma of Müllerian origin.

Gynecologic oncology reports
2025

Autologous Hematopoietic Stem Cell Transplantation for Paraneoplastic Cerebellar Degeneration.

Neurology(R) neuroimmunology &amp; neuroinflammation
2025

Exacerbation of paraneoplastic cerebellar degeneration by immune checkpoint inhibitor use in endometrial cancer.

Gynecologic oncology reports
2025

CDR2 is a dynein adaptor recruited by kinectin to regulate ER sheet organization.

The Journal of cell biology
2025

Tremor and Ataxia in Paraneoplastic Anti-Diacylglycerol Lipase Alpha (DAGLA) Cerebellitis.

Cerebellum (London, England)
2025

Paraneoplastic cerebellar degeneration combined with Lambert-Eaton myasthenia gravis syndrome in a patient positive for SOX1 antibody.

American journal of translational research
2025

Deep brain stimulation improves cerebellar tremor symptoms in paraneoplastic cerebellar degeneration: a case report.

BMC neurology
2025

Autoimmune encephalitis associated with anti-SOX1 autoantibodies in COVID-19: A case report.

IDCases
2025

Immune checkpoint inhibitor-associated paraneoplastic cerebellar degeneration in a case of extensive-stage small-cell lung cancer with pre-existing anti-SOX1 antibody.

The journal of medical investigation : JMI
2025

Imaging in paraneoplastic neurological syndromes: a comprehensive review.

Japanese journal of radiology
2025

Case Report: Anti-Yo antibody mediated paraneoplastic cerebellar degeneration in a patient with squamous cell lung carcinoma.

Frontiers in immunology
2025

Small cell lung cancer progressing into fatal ascending motor and sensory polyneuropathy despite dramatic response to chemotherapy: A case report.

Medicine
2025

Are there any differences between adult-onset cerebellitis and childhood cerebellitis?

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
2025

Hodgkin lymphoma presenting as paraneoplastic cerebellar degeneration: A case report.

SAGE open medical case reports
2025

Paraneoplastic Neurologic Syndrome Associated with Fallopian Tube Cancer: A Case Report.

Case reports in oncology
2025

Long-Term Survivor with Paraneoplastic Cerebellar Ataxia and Small-Cell Lung Cancer.

Journal of clinical medicine
2024

Roles of CDR2 and CDR2L in Anti-Yo Paraneoplastic Cerebellar Degeneration: A Literature Review.

International journal of molecular sciences
2024

Atypical Presentation of Carcinoma Breast as Paraneoplastic Cerebellar Degeneration on [18F]FDG PET/CT.

Indian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, India
2024

Paraneoplastic cerebellar degeneration - raising awareness for early diagnosis.

Neurologia i neurochirurgia polska
2024

Case report: paraneoplastic cerebellar degeneration associated with anti-Yo antibody successfully treated with ofatumumab.

Frontiers in immunology
2025

Anti-Tr/DNER Antibody-associated Paraneoplastic Neurological Syndrome Presenting Limbic Encephalitis with Anaplastic Large Cell Lymphoma.

Internal medicine (Tokyo, Japan)
2024

Case report: anti-IgLON5 disease combined with paraneoplastic cerebellar degeneration with the detection of anti-sulfatide IgG antibody, masquerading as meningoencephalitis.

BMC neurology
2024

Paraneoplastic Syndromes of the Nervous System in Patients Suffering from SCLC. A Review of the Recent Literature.

Acta medica academica
2024

FLOCCULAR SYNDROME- AN ATYPICAL PRESENTATION OF PARANEOPLASTIC CEREBELLAR DEGENERATION.

Journal of Ayub Medical College, Abbottabad : JAMC
2024

Altered exosomal miRNA profiles in patients with paraneoplastic cerebellar degeneration.

Annals of clinical and translational neurology
2024

Blood-Brain Barrier Disruption in Neuroimmunological Disease.

International journal of molecular sciences
2024

Performance Assessment of the New EUROLINE Neurologic Syndrome 15 Ag (IgG) for the Determination of Autoantibodies Associated with Neurological Disorders.

Neurology
2024

What we've learnt about autoimmune neurological diseases from neuropathology.

Revue neurologique
2024

"One a penny, two a penny", I saw the hot cross bun sign".

Clinical imaging
2024

Immune Checkpoint Inhibitor-Related Cerebellar Toxicity: Clinical Features and Comparison with Paraneoplastic Cerebellar Ataxia.

Cerebellum (London, England)
2024

Paraneoplastic neurological syndromes of small cell lung cancer.

Postepy psychiatrii neurologii
2024

Recent advances in diagnosis of immune-mediated cerebellar ataxias: novel concepts and fundamental questions on autoimmune mechanisms.

Journal of neurology
2024

Paraneoplastic syndromes in patients with melanoma.

Postepy dermatologii i alergologii
2024

Paraneoplastic Cerebellar Degeneration Revealing Non-Small Cell Lung Cancer: A Case Report.

Cureus
2024

Multi-omics profiling reveals dysregulated ribosome biogenesis and impaired cell proliferation following knockout of CDR2L.

BMC cancer
2024

Immune Ataxias: The Continuum of Latent Ataxia, Primary Ataxia and Clinical Ataxia.

Journal of integrative neuroscience
2024

18F-FDG PET/CT in assessment of paraneoplastic cerebellar degeneration as the first sign of occult fallopian tube serous cystadenocarcinoma: Case report.

RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin
2024

Gynecologic clear cell carcinoma and paraneoplastic cerebellar Degeneration: A literature review and case study.

Gynecologic oncology reports
2024

Epidemiology of paraneoplastic neurologic syndromes.

Handbook of clinical neurology
2024

Hematologic malignancies and hematopoietic stem cell transplantation.

Handbook of clinical neurology
2024

Paraneoplastic neurologic syndrome associated with gynecologic and breast malignancies.

Handbook of clinical neurology
2024

Paraneoplastic antibodies targeting intracellular antigens.

Handbook of clinical neurology
2024

Pathogenesis and immunopathology of paraneoplastic disorders.

Handbook of clinical neurology
2024

Paraneoplastic cerebellar and brainstem disorders.

Handbook of clinical neurology
2024

Paraneoplastic Cerebellar Degeneration Leading to an Early Diagnosis of Peritoneal Serous Papillary Carcinoma.

Internal medicine (Tokyo, Japan)
2024

[Blood-brain barrier breakdown and autoimmune cerebellar ataxia].

Rinsho shinkeigaku = Clinical neurology
2024

Paraneoplastic Cerebellar Degeneration Associated with Breast Cancer: A Case Report and a Narrative Review.

Brain sciences
2024

Ovarian mass Presenting as Paraneoplastic cerebellar degeneration with peripheral neuropathy and anti-Yo antibody.

BMJ case reports
2024

Cerebellar leptomeningeal enhancement: An imaging finding of rapidly progressive Purkinje cell cytoplasmic autoantibody type 1 paraneoplastic cerebellar syndrome.

Journal of neuroimmunology
2024

Cerebellar progressive multifocal leucoencephalopathy identified by the shrimp sign.

BMJ case reports
2023

Recent Advances in Immune-Mediated Cerebellar Ataxias: Pathogenesis, Diagnostic Approaches, Therapies, and Future Challenges-Editorial.

Brain sciences
2024

Favorable Outcomes in a Case of Non-paraneoplastic DNER Ataxia Treated with Immunotherapy.

Cerebellum (London, England)
2023

A not so incidental 'incidentaloma' - pediatric ganglioneuroma-associated cerebellar degeneration and super-refractory status epilepticus: case report and literature review.

Frontiers in neurology
2023

CDR2 and CDR2L line blot performance in PCA-1/anti-Yo paraneoplastic autoimmunity.

Frontiers in immunology
2024

Anti-Ma2 Antibody-Mediated Paraneoplastic Cerebellar Degeneration and Myeloneuropathy Secondary to Lymphoma.

Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society
2023

Immune-mediated ataxias: Guide to clinicians.

Parkinsonism &amp; related disorders
2023

Detection of High-Risk Paraneoplastic Antibodies against TRIM9 and TRIM67 Proteins.

Annals of neurology
2024

A retrospective study of autoimmune cerebellar ataxia over a 20-year period in a single institution.

Journal of neurology
2024

Paraneoplastic Cerebellar Degeneration Accompanied by Seropositivity for Anti-GAD65, Anti-SOX-1 and Anti-VGCC Antibodies Due to Small-cell Lung Cancer.

Internal medicine (Tokyo, Japan)
2023

Teaching NeuroImage: Paraneoplastic Cerebellar Degeneration and Antibodies to TRIM 9 and 67 Secondary to Melanoma.

Neurology
2024

Paraneoplastic Syndromes Associated with Gynecologic Neoplasms: Experience from a Tertiary Care Center in South India.

South Asian journal of cancer
2023

[Hodgkin's lymphoma: sensitive and autonomic neuropathy as a paraneoplastic manifestation].

Medicina
2023

[Immune-Mediated Cerebellar Ataxias].

Brain and nerve = Shinkei kenkyu no shinpo
2023

Cerebellar Hypermetabolism in a Hodgkin Lymphoma Leads to Diagnosis of Paucisymptomatic Cryptococcus neoformans Meningitis.

Clinical nuclear medicine
2023

Case report: Anti-CARPVIII autoantibody-associated mixed dementia.

Frontiers in psychiatry
2023

Anti-Yo paraneoplastic cerebellar degeneration in a patient with stage IV ovarian adenocarcinoma during bevacizumab maintenance therapy.

BMJ case reports
2023

Autoimmune cerebellar ataxia associated with anti-Purkinje cells antibodies: the next frontier of neuroimmunology.

Annals of translational medicine
2023

Anti-Zic4 Paraneoplastic Cerebellar Degeneration With Mesial Temporal Lobe Hyperintensity in a Patient With Papillary Thyroid Carcinoma: A Case Report and Review of the Literature.

Cureus
2023

Septin-3 autoimmunity in patients with paraneoplastic cerebellar ataxia.

Journal of neuroinflammation
2023

A cerebellar degeneration-related protein 2-like cell-based assay for anti-Yo detection in patients with paraneoplastic cerebellar degeneration.

European journal of neurology
2024

A Pilot Study to Develop Paraneoplastic Cerebellar Degeneration Mouse Model.

Cerebellum (London, England)
2022

High-grade B-cell lymphoma with gastroduodenal involvement showing paraneoplastic cerebellar degeneration: a case report.

Translational cancer research
2023

Rapid-onset paraneoplastic cerebellar degeneration successfully treated by radiotherapy and tumorectomy.

International cancer conference journal
2022

An Etiological Investigation of Paraneoplastic Cerebellar Degeneration in Ovarian Cancer Patients: A Systematic Review.

Cureus
2022

Nodular Sclerosing Hodgkin Lymphoma With Paraneoplastic Cerebellar Degeneration.

Federal practitioner : for the health care professionals of the VA, DoD, and PHS
2023

A Systematic Review on Anti-Yo/PCA-1 Antibody: Beyond Cerebellar Ataxia in Middle-Aged Women with Gynecologic Cancer.

Cerebellum (London, England)
2023

Pearls & Oy-sters: Vibration-Induced Downbeat Nystagmus: A New Cerebellar Sign Observed in Paraneoplastic Syndrome.

Neurology
2022

Rare Etiologies in Immune-Mediated Cerebellar Ataxias: Diagnostic Challenges.

Brain sciences
2022

Paraneoplastic Cerebellar Degeneration With P/Q-VGCC vs Yo Autoantibodies.

Neurology(R) neuroimmunology &amp; neuroinflammation
2022

Treatable Ataxias: How to Find the Needle in the Haystack?

Journal of movement disorders
2023

Cerebellar hypermetabolism: an alternative marker for diagnosis of paraneoplastic cerebellar degeneration.

Neurologia
2022

Anti-Zic4 paraneoplastic cerebellar degeneration in a patient with EGFR-mutated NSCLC: a case report.

Translational lung cancer research
2023

The Discovery of Anti-Yo (Anti-PCA1) Antibody in Patients with Paraneoplastic Cerebellar Degeneration: Opening a Window into Autoimmune Neurological Disease.

Cerebellum (London, England)
2022

Immune and Genetic Signatures of Breast Carcinomas Triggering Anti-Yo-Associated Paraneoplastic Cerebellar Degeneration.

Neurology(R) neuroimmunology &amp; neuroinflammation
2022

The early diagnoses and treatment of anti-Yo antibody-mediated paraneoplastic cerebellar degeneration in a patient with breast cancer: a case report.

Translational cancer research
2023

Autoimmune Cerebellar Ataxia: Etiology and Clinical Characteristics of a Case Series from China.

Cerebellum (London, England)
2022

What is in the Neuromuscular Junction Literature?

Journal of clinical neuromuscular disease
2022

Paraneoplastic cerebellar degeneration with anti-Yo antibodies and an associated submandibular gland tumor: a case report.

BMC neurology
2022

Expanding the spectrum of SOX1-antibodies in neuropathy: the coexistence of anti-SOX1 and Guillain-Barré syndrome-a case report.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
2022

Paraneoplastic syndromes in ophthalmology.

Archivos de la Sociedad Espanola de Oftalmologia
2022

Immune-Mediated Cerebellar Ataxia Associated With Neuronal Surface Antibodies.

Frontiers in immunology
2022

Anti-Ri-Associated Paraneoplastic Neurological Syndrome Revealing Breast Cancer: A Case Report.

Cureus
2021

Paraneoplastic Cerebellar Degeneration with Anti-CV2/CRMP5 Antibodies in Ovarian Cancer: Case Report and Review of the Literature.

Case reports in oncology
2022

Paraneoplastic Cerebellar Syndrome Presented as Cerebellar Hypermetabolism in a Patient With Occult Breast Carcinoma.

Clinical nuclear medicine
2021

Anti-Yo-Associated Paraneoplastic Cerebellar Degeneration: Case Series and Review of Literature.

Cureus
2022

Paraneoplastic cerebellar degeneration associated with anti-Yo antibodies in uterine papillary serous carcinoma.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
2021

Update on Paraneoplastic Cerebellar Degeneration.

Brain sciences
2022

Expression of cerebellar degeneration-related proteins CDR2 and CDR2L in human and rat brain tissue.

Journal of neuroimmunology
2022

Anti-Tr/DNER Antibody-Associated Cerebellar Ataxia: a Systematic Review.

Cerebellum (London, England)
2022

Hodgkin Lymphoma With Diplopia and Nystagmus: A Paraneoplastic Cerebellar Degeneration With Ectopic Expression of DNER Antigen on Reed-Sternberg Cells.

Clinical lymphoma, myeloma &amp; leukemia
2021

Case Report: A False Negative Case of Anti-Yo Paraneoplastic Myelopathy.

Frontiers in neurology
2021

Paraneoplastic Cerebellar Degeneration with Demyelinating Polyradiculoneuropathy in a Case of Anti-Yo Antibody-Positive Breast Cancer.

Neurology India
2021

Update in Autoimmune Movement Disorders: Newly Described Antigen Targets in Autoimmune and Paraneoplastic Cerebellar Ataxia.

Frontiers in neurology
2022

18F-FDG PET/CT Findings in a Rare Case of Paraneoplastic Vestibulocerebellar Syndrome Associated With Isolated Antiamphiphysin Antibodies.

Clinical nuclear medicine
2021

Paraneoplastic Cerebellar Degeneration: A Dilemma Resolved with Positron Emission Tomography/Computed Tomography.

Indian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, India
2022

CD8 T-cell-mediated cerebellitis directed against Purkinje cell antigen after ipilimumab for small cell lung cancer.

Neuropathology and applied neurobiology
2021

Paraneoplastic neurological syndrome: an evolving story.

Neuro-oncology practice
2021

Paraneoplastic cerebellar degeneration in platinum-responsive endometrial cancer: A case report and review of literature.

Gynecologic oncology reports
2021

Paraneoplastic cerebellar syndrome secondary to rhabdomyosarcoma: a very rare aetiology.

Neurologia
2022

PD-1-inhibitor-induced PCA-2 (MAP1B) Autoimmunity in a Patient with Renal Cell Carcinoma.

Cerebellum (London, England)
2021

Anti-Yo antibody-positive paraneoplastic cerebellar degeneration in a patient with possible cholangiocarcinoma: A case report and review of the literature.

World journal of clinical cases
2021

Recognition and management of rapid-onset gluten ataxias: case series.

Cerebellum &amp; ataxias
2021

Anti-Tr/DNER antibody paraneoplastic cerebellar degeneration preceding a very late relapse of Hodgkin Lymphoma after 12 years.

Cerebellum &amp; ataxias
2021

Paraneoplastic Cerebellar Degeneration (PCD) associated with PCA-1 antibodies in established cancer patients.

Journal of neuro-oncology
2021

Simultaneous paraneoplastic cerebellar degeneration, Lambert-Eaton syndrome and neuropathy associated with AGNA/anti-SOX1 and VGCC antibodies.

Neurological research and practice
2021

Periodic Alternating Gaze Deviation Due to Paraneoplastic Cerebellar Degeneration.

Movement disorders clinical practice
2021

Paraneoplastic cerebellar degeneration in a patient with multiple myeloma.

Leukemia &amp; lymphoma
2021

Inpatient vs Outpatient Evaluation of Suspected Paraneoplastic Cerebellar Degeneration.

Neurology. Clinical practice
2021

Lambert-Eaton Myasthenic Syndrome and Paraneoplastic Cerebellar Degeneration Associated with Merkel Cell Carcinoma with Unknown Primary: A Case Report.

Acta dermato-venereologica
2021

Voltage-Gated Calcium Channel Antibody-Induced Oropharyngeal Dysphagia Presenting as a Paraneoplastic Neurological Complication in Breast Cancer.

Cureus
2021

Autoantibodies Against the Purkinje Cell Protein RGS8 in Paraneoplastic Cerebellar Syndrome.

Neurology(R) neuroimmunology &amp; neuroinflammation
2021

Paraneoplastic Encephalitis Associated with Locally Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.

Journal of breast cancer
2021

FDG PET Unveils the Course of Paraneoplastic Cerebellar Degeneration: A Semiquantitative Analysis.

Clinical nuclear medicine
2021

Paraneoplastic cerebellar degeneration: Initial presentation of occult breast cancer.

The breast journal
2021

Acute-onset paraneoplastic cerebellar degeneration secondary to neuroendocrine carcinoma with atypical prognosis: a case report.

The Journal of international medical research
2021

Paraneoplastic cerebellar degeneration as a presenting manifestation of non-Hodgkin's lymphoma.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
2021

Paraneoplastic Cerebellar Degeneration: The Importance of Including CDR2L as a Diagnostic Marker.

Neurology(R) neuroimmunology &amp; neuroinflammation
2021

Paraneoplastic cerebellar degeneration associated with anti-Yo antibodies in an ovarian cancer case: A case report.

Gynecologic oncology reports
2021

A Rare Coexistence of Paraneoplastic Cerebellar Degeneration: Papillary Thyroid Carcinoma.

Current oncology (Toronto, Ont.)
2021

Immune-Mediated Cerebellar Ataxias: Clinical Diagnosis and Treatment Based on Immunological and Physiological Mechanisms.

Journal of movement disorders
2021

Immune-mediated ataxia with cerebellar hemiatrophy and dystonia associated with Castleman disease.

Clinical neurology and neurosurgery
2021

Paraneoplastic Cerebellar Degeneration and Lambert-Eaton Myasthenic Syndrome with SOX-1 Antibodies.

Internal medicine (Tokyo, Japan)
2021

Paraneoplastic cerebellar degeneration associated with anti-protein kinase Cgamma antibodies in a Chinese patient.

Journal of neuroimmunology
2020

Imaging Review of Paraneoplastic Neurologic Syndromes.

AJNR. American journal of neuroradiology
2020

Breast cancer associated with paraneoplastic cerebellar degeneration: A case series.

Indian journal of cancer
2020

Anti-SOX1 Antibodies in Paraneoplastic Neurological Syndrome.

Journal of clinical neurology (Seoul, Korea)
2020

Localization of CDR2L and CDR2 in paraneoplastic cerebellar degeneration.

Annals of clinical and translational neurology
2020

Potential effect of intravenous immunoglobulin against paraneoplastic cerebellar degeneration in progressive ovarian cancer.

Gynecologic oncology reports
2020

Paraneoplastic Neurological Syndromes: Study of Prevalence in a Province of the Lombardy Region, Italy.

Journal of clinical medicine
2020

Anti-Ma-associated paraneoplastic cerebellar degeneration in a patient with nodular lymphocyte-predominant Hodgkin lymphoma: a case report.

BMC neurology
2020

Paraneoplastic cerebellar degeneration heralding recurrence of fallopian tube adenocarcinoma: A case report and literature review.

Gynecologic oncology reports
2020

Plasma exchange for treating anti-Yo-associated paraneoplastic cerebellar degeneration: Case report and literature review.

Medicine
2020

Paraneoplastic cerebellar degeneration diagnosed by anti-Yo determination in a young woman with early breast cancer.

BMJ case reports
2020

[Preliminary analysis of central paroxysmal positional vertigo].

Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
2020

Paraneoplastic Cerebellar Degeneration Secondary to BRAF Mutant Melanoma Metastasis from an Occult Primary Cancer.

Case reports in oncology
2020

Antinuclear antibodies (ANA) patterns in paraneoplastic cerebellar degeneration during the course of disease and treatment protocols - A case report.

Journal of translational autoimmunity
2020

Immunological Bases of Paraneoplastic Cerebellar Degeneration and Therapeutic Implications.

Frontiers in immunology
2020

Tremor in Paraneoplastic Cerebellar Degeneration: Beyond Intention Tremor.

Annals of Indian Academy of Neurology
2020

A Case of Paraneoplastic Cerebellar Degeneration that Preceded the Diagnosis of Classical Hodgkin's Lymphoma by 16 Months.

The American journal of case reports
2020

Treatment of Primary Autoimmune Cerebellar Ataxia with Mycophenolate.

Cerebellum (London, England)
2020

Rhombencephalitis associated with isolated Zic4-antibodies in Paraneoplastic cerebellar degeneration: a case report.

BMC neurology
2020

CDR2 and CDR2L Yo Antigens in Paraneoplastic Cerebellar Degeneration.

Annals of neurology
2020

Paraneoplastic encephalitis with leukoencephalopathy in primary fallopian tube carcinoma.

Radiology case reports
2020

Paraneoplastic cerebellar degeneration in a patient with breast cancer associated with carbonic anhydrase-related protein VIII autoantibodies.

Journal of neuroimmunology
2020

Paraneoplastic cerebellar degeneration: initial presentation of mucosa-associated lymphoid tissue lymphoma in a patient with primary Sjögren's syndrome.

Chinese medical journal
2020

[Vertigo as the first manifestation of ovarian cancer].

Nederlands tijdschrift voor geneeskunde
2020

Paraneoplastic Cerebellar Degeneration in Diffuse Large B-cell Lymphoma and Review of Associated Onconeural Antibodies.

Clinical lymphoma, myeloma &amp; leukemia
2020

Clinical spectrum and diagnostic pitfalls of neurologic syndromes with Ri antibodies.

Neurology(R) neuroimmunology &amp; neuroinflammation
2020

[Ataxia - a group of heterogeneous diseases].

Lakartidningen
2020

A case of acute cerebellar ataxia with two possible etiologies: viral cerebellitis and paraneoplastic antibody-positive ovarian cancer.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
2019

Cerebellar cortical degeneration associated with feline leukemia virus infection and cerebellar lymphoma in a young cat.

Open veterinary journal
2020

Combined Cerebellar and Spinal Cord Deficits Caused by an Underlying Gynecologic Malignancy.

Case reports in oncological medicine
2020

[Paraneoplastic subacute degeneration of the cerebellum in non-small cell lung cancer and positive anti-Tr3 antibodies].

Der Nervenarzt
2020

Non-small cell lung cancer associated with late-onset Lambert-Eaton myasthenic syndrome and paraneoplastic cerebellar degeneration.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
2019

[Paraneoplastic neurologic degeneration revealing ovarian cancer recurrence].

The Pan African medical journal
2020

Epidemiology of paraneoplastic neurological syndromes: a population-based study.

Journal of neurology
2019

Rare case of paraneoplastic cerebellar degeneration secondary to high-grade serous carcinoma of tubo-ovarian origin.

BMJ case reports
2019

Stroke-Like Presentation of Paraneoplastic Cerebellar Degeneration: a Single-Center Experience and Review of the Literature.

Cerebellum (London, England)
2019

A quaint masquerader of breast cancer: Paraneoplastic cerebellar degeneration.

Neurology India
2019

Paraneoplastic cerebellar degeneration as initial presentation of renal cell carcinoma.

Cerebellum &amp; ataxias
2020

Sensitive demyelinating neuropathy associated with anti-Yo antibodies and papillary thyroid cancer.

Medicina clinica
2019

Cerebellar Ataxia With Extreme Photophobia Associated With Anti-SOX1 Antibodies.

The Neurohospitalist
2019

[Paraneoplastic cerebellar degeneration and primary fallopian cancer].

Gynecologie, obstetrique, fertilite &amp; senologie
2019

GRP78 antibodies damage the blood-brain barrier and relate to cerebellar degeneration in Lambert-Eaton myasthenic syndrome.

Brain : a journal of neurology
2019

Cerebellar Hypermetabolism in a Case of Paraneoplastic Cerebellar Syndrome With the Primary Lymphoepithelial Carcinoma in Tonsil.

Clinical nuclear medicine
2019

Paraneoplastic Cerebellar Degeneration in Nasopharyngeal Carcinoma: a Unique Association.

Cerebellum (London, England)
2019

CDR2L Is the Major Yo Antibody Target in Paraneoplastic Cerebellar Degeneration.

Annals of neurology
2019

'A Story Unheard': anti-Ta associated paraneoplastic cerebellar degeneration in a female.

Journal of community hospital internal medicine perspectives
2019

IFN-γ is a therapeutic target in paraneoplastic cerebellar degeneration.

JCI insight
2018

Variant Guillain-Barré syndrome in a patient with Hodgkin lymphoma: AMSAN.

Turk pediatri arsivi
2018

Thymic Carcinoma Associated with Cerebellar Degeneration.

European journal of case reports in internal medicine
2019

[Paraneoplastic Cerebellar Degeneration with Lambert-Eaton Myasthenic Syndrome: A Report of an Effectively Treated Case and Systematic Review of Japanese Cases].

Brain and nerve = Shinkei kenkyu no shinpo
2018

Anti-Yo antibody-mediated paraneoplastic cerebellar degeneration associated with cognitive affective syndrome in a patient with breast cancer: a case report and literature review.

Current oncology (Toronto, Ont.)
2019

Revisiting the Clinical Phenomenology of "Cerebellar Tremor": Beyond the Intention Tremor.

Cerebellum (London, England)
2018

Paraneoplastic Cerebellar Degeneration Associated With Ovarian Adenocarcinoma: A Case Report and Review of Literature.

Annals of Indian Academy of Neurology
2019

Long-Standing evolution of paraneoplastic cerebellar degeneration in a diffuse large B-cell lymphoma.

Journal of the neurological sciences
2019

The utility of anti-SOX2 antibodies for cancer prediction in patients with paraneoplastic neurological disorders.

Journal of neuroimmunology
Ver todos os 433 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Degenerescência cerebelar paraneoplásica.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Degenerescência cerebelar paraneoplásica

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Prolonged Anti-Zic4 Antibody-Positive Cerebellar Degeneration Following COVID-19 Infection.
    Neuropsychopharmacology reports· 2026· PMID 41700551mais citado
  2. Paraneoplastic cerebellar degeneration from an isolated nodal clear cell carcinoma of suspected gynecologic origin: case report and literature review.
    Journal of cancer research and clinical oncology· 2026· PMID 41593408mais citado
  3. Paraneoplastic Neuro-Ophthalmologic Symptoms as Initial Manifestation of Hodgkin Lymphoma.
    Hematology reports· 2026· PMID 41562675mais citado
  4. Autologous Hematopoietic Stem Cell Transplantation for Paraneoplastic Cerebellar Degeneration.
    Neurology(R) neuroimmunology &amp; neuroinflammation· 2025· PMID 40669039mais citado
  5. CDR2 is a dynein adaptor recruited by kinectin to regulate ER sheet organization.
    The Journal of cell biology· 2025· PMID 40637585mais citado
  6. Late-onset anti-Yo antibody-positive paraneoplastic cerebellar degeneration: a case report.
    Front Surg· 2025· PMID 41607374recente
  7. Paraneoplastic Cerebellar Syndrome Revealing Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer: A Case Report.
    Cureus· 2025· PMID 41497941recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:623626(Orphanet)
  2. MONDO:0044877(MONDO)
  3. GARD:22493(GARD (NIH))
  4. Busca completa no PubMed(PubMed)
  5. Artigo Wikipedia(Wikipedia)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Compêndio · Raras BR

Degenerescência cerebelar paraneoplásica

ORPHA:623626 · MONDO:0044877
Prevalência
1-9 / 1 000 000
CID-10
G31.8 · Outras doenças degenerativas especificadas do sistema nervoso
CID-11
Início
All ages
Prevalência
0.9553 (Europe)
MedGen
UMLS
C0393534
EuropePMC
Wikipedia
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades